Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Immunomodulator (thalidomide analogue)

Pomalidomide (Specialist drug)

Brand names: Imnovid

Pomalidomide is an oral immunomodulatory agent (thalidomide analogue) used, usually in combination, for relapsed and refractory multiple myeloma.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It modulates the immune system and exerts direct anti-myeloma and anti-angiogenic effects, acting via cereblon-mediated degradation of target transcription factors.

Prescribing in practice

  • Pomalidomide is teratogenic and is dispensed only under a Pregnancy Prevention Programme with mandatory contraception and pregnancy testing.
  • It markedly increases the risk of venous and arterial thromboembolism, so thromboprophylaxis is required.
  • Neutropenia, thrombocytopenia, and infection are common and necessitate dose adjustment and monitoring.

Monitoring

Monitor full blood count regularly, conduct pregnancy testing per the prevention programme, and watch for thromboembolic and infective complications.

Counselling the patient

  • Pregnancy must be strictly avoided; comply fully with the Pregnancy Prevention Programme, including contraception and testing.
  • Do not donate blood or sperm during treatment and for the advised period afterwards.
  • Report leg swelling, chest pain, breathlessness, fever, or signs of infection immediately.

Evidence & guidelines

The MM-003 trial demonstrated improved outcomes with pomalidomide plus low-dose dexamethasone in relapsed/refractory multiple myeloma.

Reference: NICE TA427/TA658; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways